HIV-2 Protease resistance defined in yeast cells

Retrovirology

Table 3 Definition of HIV-2 Protease susceptibility to LPV and SQV, from infected individuals

	Phenotype (transformed yeast) (% cell growth)		IC₅₀ [μM]		IC₅₀isolate/IC₅₀ROD
Protease	LPV	SQV	LPV	SQV	LPV	SQV
ROD	91.5+/-1.2	75.0+/-7.0	16.6+/-2.5	149.7+/- 7.2	1.00	1.00
MRT-1	50.0+/-3.0	71.0+/-5	48.0+/-3.2	200.1+/-5.1	2.89	1.34
MRT-7	100.0+/-4.7	98.0+/-6	10.8+/-5.0	68.9+/-6.2	0.72	0.46
MRT-8	82.0+/-7.5	55.0+/-6.3	12.5+/-1.5	553.9+/-4.2	0.66	4.23
MRT-20	71.5+/-1.2	78.0+/-3.0	23.2 +/-4.4	118.0+/-6.3	1.40	0.79
MRT-22	98.5+/-1.0	82.0+/-7.1	15.1+/-4.3	104.8+/-7.1	0.91	0.70
MRT-25	100.0+/-2.0	100.0+/-9.4	19.9+/-4.6	48.5+/-4.7	1.20	0.03
MRT-29	93.0+/-2.0	72.0+/-3.0	13.9+/-5.5	153.1+/-3.0	0.84	1.02

Viral Protease genes from HIV-2 infected individuals, as well as from the ROD isolate, were PCR amplified, sub-cloned in pRS316Gal1/10 expression vector and used to transform yeast cells. Protease susceptibility to LPV and SQV was determined by defining the % of cell growth in galactose in the presence of inhibitors (as in table 1), and IC₅₀ values were defined as in Fig 2A.

ISSN: 1742-4690